Literature DB >> 12760824

Cytomegalovirus Disease in the Highly Active Antiretroviral Therapy Era.

William Lawrence Drew1.   

Abstract

Cytomegalovirus (CMV) is a major cause of morbidity and mortality in AIDS patients. Epidemiologic studies indicate that until 10 years ago, nearly one half of HIV-infected patients eventually developed CMV end-organ disease, including chorioretinitis, esophagitis, colitis, pneumonia, and central nervous system disease. Since the introduction of highly active antiretroviral therapy (HAART) this incidence has declined dramatically. Nonetheless, patients still present with CMV disease and resistance or intolerance to HAART does develop, which may give rise to a resurgence of CMV syndromes in AIDS patients. Until recently, only intravenous ganciclovir and foscarnet were available for management of CMV infection. With the advent of additional agents, clinicians now face the challenge of optimizing therapy for individual patients. This paper reviews the most common clinical syndromes caused by CMV, the treatment options, as well as an approach to diagnosing and treating antiviral resistance.

Entities:  

Year:  2003        PMID: 12760824     DOI: 10.1007/s11908-003-0082-y

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  42 in total

1.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.

Authors:  D F Martin; B D Kuppermann; R A Wolitz; A G Palestine; H Li; C A Robinson
Journal:  N Engl J Med       Date:  1999-04-08       Impact factor: 91.245

2.  Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.

Authors:  M Mousavi-Jazi; L Schloss; W L Drew; A Linde; R C Miner; J Harmenberg; B Wahren; M Brytting
Journal:  J Clin Virol       Date:  2001-12       Impact factor: 3.168

3.  Diagnosis of cytomegalovirus (CMV) polyradiculopathy and documentation of in vivo anti-CMV activity in cerebrospinal fluid by using branched DNA signal amplification and antigen assays.

Authors:  J Flood; W L Drew; R Miner; D Jekic-McMullen; L P Shen; J Kolberg; J Garvey; S Follansbee; M Poscher
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

4.  Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group.

Authors:  D A Jabs; C Enger; J P Dunn; M Forman
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

5.  Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.

Authors:  C Tural; J Romeu; G Sirera; D Andreu; M Conejero; S Ruiz; A Jou; A Bonjoch; L Ruiz; A Arnó; B Clotet
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

6.  A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group.

Authors:  S A Spector; T Weingeist; R B Pollard; D T Dieterich; T Samo; C A Benson; D F Busch; W R Freeman; P Montague; H J Kaplan
Journal:  J Infect Dis       Date:  1993-09       Impact factor: 5.226

7.  Paradoxical activity of CMV retinitis in patients receiving highly active antiretroviral therapy.

Authors:  Mi-Kyoung Song; Rachel D Schrier; Irene L Smith; Daniel J Plummer; William R Freeman
Journal:  Retina       Date:  2002-06       Impact factor: 4.256

8.  Cytomegalovirus infections in homosexual men. An epidemiological study.

Authors:  L Mintz; W L Drew; R C Miner; E H Braff
Journal:  Ann Intern Med       Date:  1983-09       Impact factor: 25.391

9.  Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts.

Authors:  T R Vrabec; V F Baldassano; S M Whitcup
Journal:  Ophthalmology       Date:  1998-07       Impact factor: 12.079

10.  Prevalence of cytomegalovirus infection in homosexual men.

Authors:  W L Drew; L Mintz; R C Miner; M Sands; B Ketterer
Journal:  J Infect Dis       Date:  1981-02       Impact factor: 5.226

View more
  3 in total

Review 1.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Specific inhibition of human cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea small molecule.

Authors:  Thomas R Jones; Shi-Wu Lee; Stephen V Johann; Vladimir Razinkov; Robert J Visalli; Boris Feld; Jonathan D Bloom; John O'Connell
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 3.  Lower respiratory tract viral infections: Diagnostic role of exfoliative cytology.

Authors:  Rafael Martínez-Girón; Liron Pantanowitz
Journal:  Diagn Cytopathol       Date:  2017-03-01       Impact factor: 1.582

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.